Role of macrophages in cancer immunotherapy: from patient multi-omic profiles to biological function

MRC · United Kingdom government procurement

Closed September 29, 2026. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Despite the paradigm shift in cancer treatment triggered by immunotherapy, many patients fail to respond reflecting the dynamic interplay between cancer and the tumour microenvironment (TME). Monitoring this interplay is imperative to predict response to immunotherapy.

Recently, the Ciccarelli lab performed a multi-omic profile of immunotherapy-treated colorectal cancers showing that responsive tumours are characterised by deregulation of interferon-g pathways and rich infiltration of T cells and antigen-presenting tumour associated macrophages (TAMs), which engage in PD1/PDL1-mediated interactions1. The role of TAMs in the TME is unknown but they are likely to modulate anti-tumour immunity. Using spontaneous murine cancer models, the Arnold lab have identified interferon-regulated TAMs, which may be analogous to those in human cancer.

This translational and inter-disciplinary project will further characterise the role of this interferon regulated/CD74+ TAM subset(s) in the tumour microenvironment of murine and human tumours and their role in the response to immunotherapy.

This project will dissect the role of CD74+ TAMs and their role in the anti-tumour immune response through the following overarching project aims:

1) Employ spatial transcriptomics and imaging mass cytometry of immunotherapy-treated human gastrointestinal cancers and murine tumours to deeply phenotype (CD74+ /interferon-regulated TAMs and characterise their interactions with T cells in tissues sections.

2) Analyse transcriptomic datasets and employ computational approaches alongside in vivo models and in vitro culture techniques to identify candidate mediators of CD74+ TAM polarisation and recruitment at the tumour site, with a primary focus on studying the role of IFN-gamma as a key candidate polarisation molecule.

3) Mechanistically resolve the relationship between TAMs and their modulation of T cell responses via gene knockout and therapeutic intervention in murine models of...

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch Development
PublishedSeptember 30, 2022
Procurement stageActive solicitation
ClosedSeptember 29, 2026
StatusClosed — no longer accepting responses
Official sourceView original notice
Last verifiedAugust 10, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Browse Similar Open Opportunities in United Kingdom

Rotation year
Title of project: Evaluation of the quantitative accuracy and radiation dosimetry of an advanced pre-clinical multipinhole SPECT/CT theranostic imag
Discerning MCT1s role in chromatin remodelling and metabolomics changes in cancer progression
Leveraging real world data to characterise the long term impact of COVID-19
Bacterial antibiotic resistance: structure, mechanism and inhibition of ABC transporters responsible for drug efflux and cell wall biogenesis.
Characterising the role of TEX12 in centrosome and cilia development
Allogeneic Chondroprogenitor Therapy (Phase II) (ACT2)
Dectin-1-mediated suppression of protective anti-mycobacterial immunity

See every United Kingdom Research Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research Development intelligence report in your inbox

A personalized report on United Kingdom Research Development opportunities, emailed in 5-10 minutes. One per month, no account needed.